Efficacy and Safety of Bone Marrow-Derived Mesenchymal Stem Cells for Chronic Antibody-Mediated Rejection After Kidney Transplantation- A Single-Arm, Two-Dosing-Regimen, Phase I/II Study

Efficacy and Safety of Bone Marrow-Derived Mesenchymal Stem Cells for Chronic Antibody-Mediated Rejection After Kidney Transplantation- A Single-Arm, Two-Dosing-Regimen, Phase I/II Study

ObjectiveTo investigate the efficacy and safety of bone marrow-derived mesenchymal stem cells (BM-MSCs) on chronic active antibody-mediated rejection (cABMR) in the kidney allograft.MethodsKidney recipients with biopsy-proven cABMR were treated with allogeneic third-party BM-MSCs in this open-label,...

Full description

Bibliographic Details
Main Authors: Yongcheng Wei, Xiaoyong Chen, Huanxi Zhang, Qun Su, Yanwen Peng, Qian Fu, Jun Li, Yifang Gao, Xirui Li, Shicong Yang, Qianyu Ye, Huiting Huang, Ronghai Deng, Gang Li, Bowen Xu, Chenglin Wu, Jiali Wang, Xiaoran Zhang, Xiaojun Su, Longshan Liu, Andy Peng Xiang, Changxi Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Immunology
Subjects:
mesenchymal stem cells
kidney transplantation
antibody-mediated allograft rejection
stem cell therapy
alloimmunity
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.662441/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.662441/full

Similar Items